Quinacrine, an antimalarial agent and NRF2 inhibitor, reversed 5-fluorouracil (5-FU) resistance in colorectal cancer (CRC) cell lines by decreasing the expression of NRF2 [47]. This evidence concerns the gene NFE2L2 and colorectal carcinoma.